Core Ethical Principles in Pediatric Genetics

Respect for autonomy: Acknowledging an individual’s right to self-determination, which in pediatrics translates to preserving the child’s right to an open future until they reach decisional capacity.
Beneficence: Acting in the best interest of the patient, ensuring genetic testing offers actionable clinical, psychosocial, or reproductive benefits.
Non-maleficence: Avoiding psychological harm, such as anxiety or altered family dynamics, and social harm, such as genetic discrimination or stigmatization.
Justice: Ensuring fair and equitable access to expensive genetic testing and counseling services across all socioeconomic and ethnic groups. Database biases currently overrepresent European ancestry, exacerbating healthcare inequalities.

Modality-Specific Ethical Considerations

Testing Modality	Key Ethical Concerns	Current Recommendations
Diagnostic Testing	Possibility of Variants of Uncertain Significance (VUS) and potential lack of a definitive cure.	Mandates thorough pre-test counseling regarding uncertainties.
Carrier Testing	Infringes on future autonomy to know carrier status; risks parental stigmatization.	Defer in asymptomatic minors until reproductive age unless immediate childhood health implications exist.
Predictive Testing (Childhood-Onset)	Psychosocial burden on the family.	Highly recommended if early intervention reduces morbidity or mortality.
Predictive Testing (Adult-Onset)	Violates the child’s right to remain in ignorance; induces severe psychological distress; offers no immediate medical benefit.	Strongly discouraged and generally deferred until the child reaches maturity.
Newborn Screening	Bypasses traditional informed consent (opt-out models); debates over scope expansion and residual blood spot retention.	Support mandatory offering but respect informed parental refusal.
Pharmacogenomic Testing	Risk of incidentally uncovering non-pharmacological disease risks.	Acceptable with permission, but broader implications must be discussed prior to testing.

Minors generally lack legal capacity, placing the burden of consent on parents acting as surrogates based on the best interest standard.
Developmentally appropriate children (typically aged seven and above) should be involved and provide assent without coercion.
Conflicts between adolescent autonomy and parental requests require careful mediation and ethics committee involvement.

Fear exists that genetic data could be used adversely by health insurers, life insurance providers, or employers.
The Genetic Information Nondiscrimination Act (GINA) protects Americans from discrimination in health insurance and employment, but does not extend to life, disability, or long-term care insurance.

Diagnosing an inherited condition in a child implies risks for extended family members.
Pediatricians face a conflict between maintaining patient confidentiality and warning at-risk relatives.
Standard practice empowers parents to share information with relatives using family letters rather than physicians breaching confidentiality.

Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) often reveal pathogenic variants unrelated to the primary testing indication.
Laboratories recommend reporting actionable secondary findings, raising dilemmas over whether parents can opt-out of adult-onset findings for their children.
Pre-test counseling is critical to determine parent preferences regarding medically actionable versus non-actionable secondary findings.

Commercial genetic kits marketed directly to the public lack physician intermediaries.
Strongly discouraged for minors due to lack of adequate counseling, questionable clinical validity, and privacy risks.

Genomic research relies on large datasets, raising concerns over broad versus specific parental consent for future unspecified research.
Ethical obligations exist regarding the duty to re-contact families if a VUS is later reclassified as pathogenic.